Royalty Pharma 

Yahoo Finance • 21 days ago

Caledonia (Private) Investments Doubles Down on Coursera Stock: Is it Time to Buy?

Key Points Caledonia increased its Coursera stake by 1,935,803 shares, with a net position change of $44.43 million. The transaction accounted for 0.34% of 13F reportable assets under management. Post-trade Coursera position: 9,313,631 sh... Full story

Yahoo Finance • 22 days ago

Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement

NEW YORK and SOUTH SAN FRANCISCO, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Denali Therapeutics, Inc. (Nasdaq: DNLI) today announced a $275 million synthetic royalty funding agreement based on future... Full story

Yahoo Finance • 22 days ago

Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement

SOUTH SAN FRANCISCO, Calif. and NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) and Royalty Pharma plc (Nasdaq: RPRX) today announced a $275 million synthetic royalty funding agreement based on future... Full story

Yahoo Finance • 30 days ago

Royalty Pharma to Present at Upcoming Investor Conferences

NEW YORK, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of December: Citi’s 2025 Global Healthcare Conference... Full story

Yahoo Finance • last month

Top pharmaceutical stocks by Quant to focus on as Novo Nordisk slides

[Close-up of a male hand holding a pill bottle pouring medication into his hand] Trevor Williams The recent news [https://seekingalpha.com/news/4525254-novo-nordisk-slides-as-ozempic-pill-fails-to-slow-alzheimers-disease-progression-in-la... Full story

Yahoo Finance • last month

Vaximm and BCME link on oral cancer immunotherapy platform

OSR Company Vaximm has signed a non-binding term sheet with Swiss-based life sciences investor BCM Europe (BCME) for a potential exclusive worldwide licence for Vaximm’s oral cancer immunotherapy platform, VXM01. The agreement includes an... Full story

Yahoo Finance • last month

Eli Lilly Leads Three Stocks Near Buy Points

The stock market continued its sell-off Friday, but a few stocks ascended in buy zones and hovered near new highs. Eli Lilly, for one, hit an all-time high. Another is Valero, which has edged into a buy zone above an entry at 178.43, accor... Full story

Yahoo Finance • 2 months ago

Royalty Pharma Q3 Profit Falls

(RTTNews) - Royalty Pharma plc (RPRX) reported weaker results for the third quarter ended September 30, 2025, as higher operating expenses and increased provisions weighed on profitability, despite a modest rise in revenue. Net income att... Full story

Yahoo Finance • 2 months ago

Sector Update: Health Care Stocks Rise Late Afternoon

Health care stocks advanced late Tuesday afternoon with the NYSE Health Care Index and the Health Ca PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 2 months ago

What Do Analysts Think About Royalty Pharma Plc (RPRX)?

Royalty Pharma Plc (NASDAQ:RPRX) is one of the most profitable biotech stocks to buy. On October 10, Morgan Stanley analyst Terence Flynn slashed the price target on Royalty Pharma Plc (NASDAQ:RPRX) to $54 from $55 while keeping an overwei... Full story

Yahoo Finance • 2 months ago

Royalty Pharma declares $0.22 dividend

* Royalty Pharma (NASDAQ:RPRX [https://seekingalpha.com/symbol/RPRX]) declares $0.22/share quarterly dividend [https://seekingalpha.com/pr/20270270-royalty-pharma-declares-fourth-quarter-2025-dividend], in line with previous. * Forward... Full story

Yahoo Finance • 2 months ago

Royalty Pharma Declares Fourth Quarter 2025 Dividend

NEW YORK, Oct. 17, 2025 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2025 of $0.22 per Class A ordinary share. The dividend will be paid... Full story

Yahoo Finance • 3 months ago

Royalty Pharma to Announce Third Quarter 2025 Financial Results on November 5, 2025

NEW YORK, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its third quarter 2025 financial results on Wednesday, November 5, 2025 before the U.S. financial markets open. The company... Full story

Yahoo Finance • 3 months ago

Revolution Medicines, Inc. (RVMD) Insider Sells Shares

Revolution Medicines, Inc. (NASDAQ:RVMD) is among the most promising biotech stocks to buy according to hedge funds. On September 24, 2025, General Counsel and Officer of Revolution Medicines, Inc. (NASDAQ:RVMD), Jeff Cislini, offloaded 1,... Full story

Yahoo Finance • 3 months ago

Royalty Pharma Appoints Dr. Ted W. Love As Lead Independent Director

NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that the independent directors of the Board have unanimously appointed Dr. Ted W. Love, an independent director since 2020, as Lead Independen... Full story

Yahoo Finance • 3 months ago

Peek Under The Hood: USSG Has 11% Upside

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied... Full story

Yahoo Finance • 3 months ago

Royalty Pharma to Present at Bernstein’s 2nd Annual Healthcare Forum

NEW YORK, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at Bernstein’s 2nd Annual Healthcare Forum on Tuesday, September 23, 2025 at 2:50 p.m. ET. The we... Full story

Yahoo Finance • 3 months ago

Royalty Pharma plc (RPRX) Reports 20% Portfolio Growth, Posts $727M in Q2 Receipts

In this article, we will be taking a look at the 12 Cheap Healthcare Stocks to Buy Now. Royalty Pharma plc is one of them. Royalty Pharma plc (NASDAQ:RPRX), a biopharmaceutical company specializing in acquiring and managing royalties from... Full story

Yahoo Finance • 3 months ago

Royalty Pharma plc (RPRX) Commits $300M to Zenas’ Obexelimab Program

In this article, we will be taking a look at the 11 Best Performing Biotech Stocks So Far in 2025. Royalty Pharma plc is one of them. Royalty Pharma plc (NASDAQ:RPRX) tops our list for being one of the best performing stocks. It is a lead... Full story

Yahoo Finance • 3 months ago

Royalty Pharma Investor Day Highlights Strong Growth Outlook and Company’s Plans to Drive Value Creation

Royalty Pharma plc On track to deliver Portfolio Receipts of $4.7 billion or more by 2030, significantly ahead of consensus Goal to achieve at least mid-teens average annual total shareholder return over next 5 years with significant upsi... Full story